Harrow (HROW) Expected to Announce Earnings on Monday

Harrow (NASDAQ:HROW) is expected to issue its quarterly earnings data after the market closes on Monday, March 17th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $58.41 million for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Harrow Stock Performance

NASDAQ:HROW opened at $23.01 on Friday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The firm has a 50-day moving average of $30.45 and a two-hundred day moving average of $38.85. The stock has a market cap of $819.50 million, a P/E ratio of -24.48 and a beta of 0.69. Harrow has a 1-year low of $9.30 and a 1-year high of $59.23.

Analyst Upgrades and Downgrades

HROW has been the subject of a number of analyst reports. HC Wainwright initiated coverage on shares of Harrow in a research report on Thursday, February 6th. They issued a “buy” rating and a $57.00 price objective for the company. B. Riley reduced their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a research report on Wednesday, December 4th.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.